Award Number: W81XWH-10-1-0810

TITLE: Adaptive Disclosure: A Combat-Specific PTSD Treatment

PRINCIPAL INVESTIGATOR: Brett Litz, Ph.D.

CONTRACTING ORGANIZATION: Boston VA Research Institute
Boston, MA 02130

REPORT DATE: October 2012

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Adaptive Disclosure: A Combat-Specific PTSD Treatment

Brett Litz, Ph.D.
Maria Steenkamp, Ph.D.
E-Mail: brett.litz@va.gov

Boston VA Research Institute
Boston, MA 02130

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland  21702-5012

Many troops return from deployment with mental health problems related to their experiences. One such problem is posttraumatic stress disorder (PTSD), which involves symptoms such as persistent unwanted memories of traumatic events, avoidance of reminders of the events, excessive watchfulness, jumpiness and irritability. Current therapies for PTSD focus chiefly on fear related to life-threat and were developed chiefly on civilians. We developed and piloted tested an early psychological treatment for PTSD designed specifically for service members who suffer not only life-threat, but traumatic loss and inner conflicts from morally injurious experiences. AD is an eight-session treatment that helps Marines to identify unhelpful beliefs about a traumatic event and find ways to move forward. Preliminary data suggests that AD is acceptable to Marines, safe and feasible to implement, and that it reduces PTSD and depression. The primary objective of this randomized controlled non-inferiority trial is to determine whether Adaptive Disclosure (AD), a new combat-specific psychotherapy for PTSD, is comparable in efficacy to Cognitive Processing Therapy, cognitive only version (CPT-C) in terms of its impact on deployment-related psychological problems (specifically PTSD and depression) and functioning. As secondary aims, we have specified some comparisons in which we believe that AD will be superior to CPT-C (degree of change in posttraumatic grief, moral injury, resilience, and posttraumatic growth, as well as degree of treatment acceptability) and we propose to evaluate a posited mechanism of change (trauma-related cognition). There are no up-to-date findings as data collection has not yet begun.

Active-duty, Marine Corps, Posttraumatic stress disorder, Cognitive Therapy
Table of Contents

Introduction .................................................................................................................. 4

Body ............................................................................................................................. 5

Key Research Accomplishments ................................................................................. 6

Reportable Outcomes .................................................................................................. 6

Conclusion .................................................................................................................... 6

References .................................................................................................................... 7
INTRODUCTION

More than 2 million U.S. troops have served in the wars in Afghanistan and Iraq. Findings from epidemiologic studies of infantry troops in the early stages of the wars suggest that 10-18% of combat troops experience deployment-related psychological health problems, such as posttraumatic stress disorder (PTSD; e.g., Hoge et al., 2004; see Litz & Schlenger, 2009). Once service members and new Veterans develop sustained mental health problems related to combat and operational stress, many are at risk to remain chronic across the lifespan (e.g., Kessler et al., 1995; Kulka et al., 1990; Prigerson et al., 2001). Thus, primary and secondary prevention of PTSD is a critical challenge for the military and the VA (e.g., Litz & Bryant, 2009). We have developed a novel intervention, Adaptive Disclosure (AD), to address these needs. AD is a hybrid and extension of evidence-informed cognitive-behavioral therapy strategies packaged and sequenced to target the three high base-rate combat and operational traumas, namely, life-threat trauma, loss (principally traumatic loss), and experiences that produce inner moral conflict (Steenkamp et al., 2011). AD employs a Prolonged Exposure (PE) strategy (imaginal emotional processing of an event) and cognitive-therapy-based techniques used in Cognitive Processing Therapy (CPT), but also includes gestalt-therapy techniques designed to target loss and moral injury. In our open pilot trial, we demonstrated treatment acceptability among Marines and large reductions in PTSD and comorbid symptoms. The primary objective of the current randomized control non-inferiority trial is to determine whether AD is as least as effective as CPT, cognitive only version (CPT-C), in terms of its impact on deployment-related psychological health problems (specifically PTSD and depression) and functioning.
Statement of Work (SOW)

1. **Regulatory Review and IRB Approval (delayed by 18 months):**
   (1) Prepare and submit human subjects protection application to UCSD IRB, VA Research and Development (R&D) Committee, IRB for Camp Pendleton, Boston IRB/R&D and Army ORP. IRBs have been approved by UCSD IRB, VA Boston IRB/R&D, and Camp Pendleton IRB. HRPO approval was obtained in June 2012.
   (2) Establish weekly meetings for principal investigators for study planning and initiation. Biweekly meetings and conference calls with principal investigators have been established; they are currently occurring on an as-need basis but will be attended weekly once recruitment begins.

2. **Patient Recruitment, Enrollment, Intervention:**  
   1) Identify and recruit potential participants;  
   2) monitor enrollment progress at clinics;  
   3) provide ongoing supervision for therapists;  
   4) collect data from study participants [pre-treatment through 32 weeks];  
   5) conduct audio recording for on-going adherence and provide prompt feedback to assessors and therapists;  
   6) collect and report adverse events and serious adverse events;  
   7) transport deidentified data to Boston for entry and secure storage;  
   8) ongoing data quality monitoring. Due to the much longer than expected process of obtaining legal and regulatory approval through the Naval Medical Center San Diego, enrollment did not begin this year as planned.

3. **Hire and Train Study Personnel:** All Boston study personnel are hired and trained and ready to begin data collection. All preparatory tasks have been finalized.

---

**Site Location Information**

**Site 1: San Diego [Veterans Medical Research Foundation (VMRF)]**  
9500 Gilman Dr. (MC 0855)  
La Jolla, CA 92093-0855  
PI: Ariel J. Lang, Ph.D., M.P.H.  
Human use at Camp Pendleton.

**Site 2: Boston [Boston VA Research Institute (BVARI)]**  
150 South Huntington Avenue,  
Room 11B-60  
Boston, MA 02130  
PI: Brett Litz, Ph.D.  
No human or animal use at this site.

**Site 3: UCSD**  
9500 Gilman Dr.  
La Jolla, CA 92093  
PI: William Nash, M.D.  
No human or animal use at this site.
### Gantt Chart for SOW

<table>
<thead>
<tr>
<th>Preparatory Phase: Set-up, Regulatory Review and Approvals</th>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRB and VA R&amp;D Committee approvals</td>
<td>VMRF,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boston</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Army ORP approval</td>
<td>VMRF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hire and train staff</td>
<td>VMRF,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boston, UCSD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Develop database</td>
<td>Boston</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Recruitment, Enrollment and Intervention

<table>
<thead>
<tr>
<th>Activity</th>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recruit and enroll participants</td>
<td>VMRF,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>UCSD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deliver AD and CPT-C</td>
<td>VMRF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data collection</td>
<td>VMRF,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boston</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supervise assessors and therapists</td>
<td>VMRF,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boston, UCSD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data quality monitoring</td>
<td>VMRF,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boston</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Data Collection and Close-out

<table>
<thead>
<tr>
<th>Activity</th>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete data collection</td>
<td></td>
<td></td>
<td></td>
<td>VMRF,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Boston</td>
</tr>
<tr>
<td>Complete database</td>
<td></td>
<td></td>
<td></td>
<td>Boston</td>
</tr>
</tbody>
</table>

#### Analysis, Writing & Dissemination

<table>
<thead>
<tr>
<th>Activity</th>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete data analysis</td>
<td></td>
<td></td>
<td></td>
<td>Boston</td>
</tr>
<tr>
<td>Prepare reports, manuscripts,</td>
<td></td>
<td></td>
<td></td>
<td>VMRF,</td>
</tr>
<tr>
<td>presentations</td>
<td></td>
<td></td>
<td></td>
<td>Boston, UCSD</td>
</tr>
</tbody>
</table>

### KEY RESEARCH ACCOMPLISHMENTS

Recruitment has not yet begun. No data have been collected in the past year.

### REPORTABLE OUTCOMES

None at this time.

### CONCLUSION

Recruitment has not yet begun. No data have been collected in the past year.
REFERENCES


